Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced it granted inducement awards on august 31, 2023. two individuals were hired by adicet in august 2023. in the aggregate, adicet granted new hires non-qualified stock options to purchase 12,200 shares of adicet's common stock with an exercise price of $2.00 per share, the closing price.
ACET Ratings Summary
ACET Quant Ranking